NovoCure (NVCR) Change in Receivables (2017 - 2023)

NovoCure has disclosed Change in Receivables across 7 years of filings, most recently posting -$2.6 million for Q3 2023.

• Change in Receivables for Q3 2023 came in at -$2.6 million, up 77.07% year-over-year; the trailing twelve-month figure through Sep 2023 was -$20.3 million (down 165.14% YoY), and the FY2022 annual result was -$2.5 million, up 51.67% from the prior year.
• Change in Receivables came in at -$2.6 million for Q3 2023 at NovoCure, up from -$6.9 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $19.7 million in Q1 2020 to a low of -$14.5 million in Q1 2023.
• The 5-year median for Change in Receivables is $2.0 million (2019), against an average of $1.8 million.
• Across the five-year window, Change in Receivables soared 868.47% in 2020 and plunged 409.23% in 2022, its largest moves.
• NovoCure's Change in Receivables stood at $19.5 million in 2019, then slumped by 116.44% to -$3.2 million in 2020, then jumped by 57.93% to -$1.3 million in 2021, then soared by 379.96% to $3.8 million in 2022, then sank by 170.06% to -$2.6 million in 2023.
• The last three Change in Receivables figures came in at -$2.6 million (Q3 2023), -$6.9 million (Q2 2023), and -$14.5 million (Q1 2023), per Business Quant data.